Fundz

Alphaeon Corp reported raising $5.5 Million in an initial SEC Form D filing, from an offering of $55 Million

PRIVATEAug 10, 2016$5.5M of $55M raised

Amount Raised

$5.5 Million

$5.5 Million sold, per SEC Form D (first sale Aug 10, 2016)

Round Type

Venture

IrvineBiotechnologyHealthcareHealth CareTherapeuticsBiopharma

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as AEON Biopharma that raised within 45 days of this round, from Fundz verified event records.

  • Cocrystal Pharma, Inc. raised $4M (Seed) on September 15, 2016.
  • Recursion Pharmaceuticals raised $32M on September 14, 2016.
  • Recursion Pharmaceuticals raised $13M on September 14, 2016.
  • Recursion Pharmaceuticals raised $4.1M (Seed) on September 14, 2016.
  • ClearPoint Neuro raised $6M on September 13, 2016.
  • AIM ImmunoTech raised $33K (Pre-Seed) on September 2, 2016.

Who to call at AEON Biopharma, and when

A new round usually means AEON Biopharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AEON Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AEON Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AEON Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AEON Biopharma

Location

5 PARK PLAZA

Irvine, California, United States

About

AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AEON Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AEON Biopharma's next move

See what Strategic adds

AEON Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.